Foreword; Preface; Acknowledgements; Contents; Contributors; 1: Hodgkin Lymphoma; 1.1 Epidemiology; 1.2 Clinical Presentation; 1.3 Diagnosis; 1.4 Pathology and Classification; 1.5 Staging; 1.6 Prognostic Factors at Baseline; 1.7 Nodular Lymphocyte Predominant Hodgkin Lymphoma; Further Reading; 2: Pathology of Hodgkin Lymphoma; 2.1 NLPHL: Clinical, Biological, Morphological and Immunophenotipical Features; 2.2 cHL: Clinical, Biological, Morphological and Immunophenotipical Features; 2.3 cHL Variants; 2.3.1 Nodular Sclerosis; 2.3.2 Mixed Cellularity; 2.3.3 Lymphocyte Rich

2.3.4 Lymphocyte DepletedFurther Reading; References; 3: Management of Hodgkin Lymphoma; 3.1 Baseline Evaluation; 3.2 Historical overview of HL treatment; 3.3 Upfront Treatment Modalities; 3.4 Early Stage Favourable cHL; 3.5 Early Stage Unfavourable cHL; 3.6 Treatment of Advanced-Stage Disease; 3.7 Follow-Up Evaluation; 3.8 Management of Refractory and Relapsed Disease; 3.9 Novel Agents; 3.10 Management of NLPHL; Further Reading; 4: Radiological Imaging in Lymphoma; 4.1 Introduction; 4.2 Primary Diagnosis/Staging; 4.3 Response Assessment; 4.4 The Future; References

5: 18F-FDG PET/CT in Hodgkin's Lymphoma5.1 Pretreatment Assessment; 5.1.1 Staging; 5.1.2 Prognostication; 5.2 Interim Scanning; 5.2.1 Prognostication; 5.3 Response-Adapted Therapy; 5.4 End of Treatment Scanning; 5.5 PET Before High-Dose Chemotherapy or Transplant; 5.6 Surveillance; 5.7 Radiotherapy Planning; 5.8 Combined Scanning of PET/CT with Contrast-Enhanced Diagnostic Quality CT; 5.9 Scan Interpretation; References; 6: 18F-FDG PET/CT: Normal Variants, Artefacts and Pitfalls in Lymphoma; 6.1 Introduction; 6.2 General PET/CT Issues; 6.2.1 False Positive

6.2.2 False Negative6.3 Anatomy Based; 6.3.1 Lymphatic Sites; 6.3.1.1 Waldeyer's ring; 6.3.1.2 Lymph Nodes; 6.3.1.3 Thymus; 6.3.1.4 Spleen; 6.3.2 Extralymphatic Sites; 6.3.2.1 CNS; 6.3.2.2 Thyroid; 6.3.2.3 Lungs; 6.3.2.4 Liver; 6.3.2.5 GI; 6.3.2.6 Renal Lymphoma; 6.3.2.7 Bone Marrow; 6.3.2.8 Skin; Further Reading; 7: PET/CT in Hodgkin's Lymphoma: Teaching Cases; 7.1 Case 1: Upstaging of Disease with PET/CT; 7.1.1 Teaching Points; 7.2 Case 2: Early Stage Unfavourable Disease; 7.2.1 Teaching Points; 7.3 Case 3: Splenic Involvement on PET/CT; 7.3.1 Teaching Points

7.4 Case 4: Reactive Marrow Activity Pre-Treatment7.4.1 Teaching Points; 7.5 Case 5: Bone Marrow Involvement; 7.5.1 Teaching Points; 7.6 Case 6: Brown Fat Activity; 7.6.1 Teaching Points; 7.7 Case 7: Thymic Hyperplasia; 7.7.1 Teaching Points; 7.8 Case 8: Reactive Bone Marrow and Spleen Activation; 7.8.1 Teaching Points; 7.9 Case 9: Metabolic Remission; 7.9.1 Teaching Points; 7.10 Case 10: Interim PET Scan with Uptake Score of 3; 7.10.1 Teaching Points; 7.11 Case 11: Interim PET Scan with Uptake Score of 4; 7.11.1 Teaching Points